Mölsä Melissa, Heikkinen Tuija, Hakkola Jukka, Hakala Kristo, Wallerman Ola, Wadelius Mia, Wadelius Claes, Laine Kari
Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland.
Clin Pharmacol Ther. 2005 Aug;78(2):123-31. doi: 10.1016/j.clpt.2005.04.014.
In vitro and animal experiments suggest that P-glycoprotein forms a functional barrier between maternal and fetal blood circulation in the placenta, thus protecting the fetus from exposure to xenobiotics during pregnancy. In this study we aimed to characterize the role of P-glycoprotein in the blood-placental barrier by use of dually perfused human placenta.
Twenty-eight human placentas were obtained after delivery, and both the maternal side and the fetal side were perfused for 2 hours. Saquinavir was used as a probe drug for P-glycoprotein-dependent active transfer, and PSC833 (valspodar) or GG918 was used as an inhibitor of P-glycoprotein function in a maternal-to-fetal and fetal-to-maternal perfusion setting. Genotyping for ABCB1 (C3435T and G2677A/T) polymorphism and quantification of P-glycoprotein expression were done for each placenta.
The fetal-to-maternal transfer of saquinavir was 108-fold higher (P = .003) compared with transfer from the maternal to the fetal direction. Preperfusion with PSC833 increased the placental transfer of saquinavir by 7.9-fold (P < .001), and preperfusion with GG918 increased it by 6.2-fold (P < .001). The end-perfusion transfer (percentage) of saquinavir at 120 minutes was 11-fold (P < .001) and 6-fold (P < .001) higher in placentas preperfused with PSC833 and GG918, respectively, compared with control. However, PSC833 had no effect on the transfer of saquinavir from the fetal to the maternal direction (P = .79). P-glycoprotein expression was correlated with the PSC833-induced change in the saquinavir transfer (r = 0.75, P = .086). ABCB1 polymorphism did not affect the PSC833- or GG918-induced change in the saquinavir transfer.
P-glycoprotein has a major functional role in the human blood-placental barrier but a negligible role in the removal of substances from the fetal circulation to maternal blood. Pharmacologic blockade of P-glycoprotein function can lead to disruption of the blood-placental barrier and increase the transfer of P-glycoprotein substrates to the fetal side by several-fold, which may be a noteworthy mechanism for teratogenicity.
体外和动物实验表明,P-糖蛋白在胎盘的母血和胎儿血液循环之间形成功能性屏障,从而在孕期保护胎儿免受外源性物质的影响。在本研究中,我们旨在通过使用双灌注人胎盘来阐明P-糖蛋白在血-胎盘屏障中的作用。
分娩后获取28个人胎盘,对母体侧和胎儿侧均进行2小时灌注。将沙奎那韦用作P-糖蛋白依赖性主动转运的探针药物,并在母体到胎儿和胎儿到母体的灌注设置中使用PSC833(伐司朴达)或GG918作为P-糖蛋白功能的抑制剂。对每个胎盘进行ABCB1(C3435T和G2677A/T)多态性基因分型和P-糖蛋白表达定量。
与从母体到胎儿方向的转运相比,沙奎那韦从胎儿到母体的转运高出108倍(P = 0.003)。用PSC833预灌注使沙奎那韦的胎盘转运增加7.9倍(P < 0.001),用GG918预灌注使其增加6.2倍(P < 0.001)。与对照组相比,在120分钟时,用PSC833和GG918预灌注的胎盘沙奎那韦的终末灌注转运(百分比)分别高出11倍(P < 0.001)和6倍(P < 0.001)。然而,PSC833对沙奎那韦从胎儿到母体方向的转运没有影响(P = 0.79)。P-糖蛋白表达与PSC833诱导的沙奎那韦转运变化相关(r = 0.75,P = 0.086)。ABCB1多态性不影响PSC833或GG918诱导的沙奎那韦转运变化。
P-糖蛋白在人血-胎盘屏障中起主要功能作用,但在将物质从胎儿循环清除到母体血液中的作用可忽略不计。P-糖蛋白功能的药理学阻断可导致血-胎盘屏障破坏,并使P-糖蛋白底物向胎儿侧的转运增加数倍,这可能是致畸性的一个值得注意的机制。